Salt substitutes lower cardiovascular risk in the general population — but WHO's 2025 guidance excluded people with CKD over hyperkalaemia concerns, and the landmark SSaSS trial under-represented them. So where does that leave your patients? Two experts debate the benefit and caution cases, including selective use in CKD, in a scene-setter followed by opposing positions, cross-examination and an audience vote. You'll leave better equipped to advise people with kidney disease on salt substitutes amid genuinely conflicting evidence.
| Time | Session |
|---|---|
|
16:15
16:35
|
Salt substitutes in CKD: the benefit case, including selective use
|
|
16:35
16:55
|
Salt substitutes in CKD: the caution case — hyperkalaemia risk
|
|
16:55
17:15
|
Q&A
|